Clearpoint Neuro Inc Financials
This page shows Clearpoint Neuro Inc (CLPT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Clearpoint Neuro Inc has an operating margin of -62.9%, meaning the company retains $-63 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -93.7% the prior year.
Clearpoint Neuro Inc's revenue surged 31.0% year-over-year to $31.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Clearpoint Neuro Inc carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.22, Clearpoint Neuro Inc holds $3.22 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Clearpoint Neuro Inc generated -$9.0M in operating cash flow, capex of $275K consumed most of it, leaving -$9.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Clearpoint Neuro Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Clearpoint Neuro Inc generates $0.48 in operating cash flow (-$9.0M OCF vs -$18.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Clearpoint Neuro Inc earns $-22.6 in operating income for every $1 of interest expense (-$19.7M vs $872K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Clearpoint Neuro Inc generated $31.4M in revenue in fiscal year 2024. This represents an increase of 31.0% from the prior year.
Clearpoint Neuro Inc's EBITDA was -$18.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.0% from the prior year.
Clearpoint Neuro Inc generated -$9.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 35.8% from the prior year.
Clearpoint Neuro Inc reported -$18.9M in net income in fiscal year 2024. This represents an increase of 14.4% from the prior year.
Clearpoint Neuro Inc earned $-0.70 per diluted share (EPS) in fiscal year 2024. This represents an increase of 22.2% from the prior year.
Clearpoint Neuro Inc held $20.1M in cash against $0 in long-term debt as of fiscal year 2024.
Clearpoint Neuro Inc had 28M shares outstanding in fiscal year 2024. This represents an increase of 12.0% from the prior year.
Clearpoint Neuro Inc's gross margin was 60.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 4.1 percentage points from the prior year.
Clearpoint Neuro Inc's operating margin was -62.9% in fiscal year 2024, reflecting core business profitability. This is up 30.8 percentage points from the prior year.
Clearpoint Neuro Inc's net profit margin was -60.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 32.0 percentage points from the prior year.
Clearpoint Neuro Inc invested $12.4M in research and development in fiscal year 2024. This represents an increase of 5.8% from the prior year.
Clearpoint Neuro Inc invested $275K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 61.6% from the prior year.
CLPT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M-3.8% | $9.2M+8.6% | $8.5M+9.2% | $7.8M-1.1% | $7.9M+2.9% | $7.6M+12.2% | $6.8M+18.2% | $5.8M |
| Cost of Revenue | $3.3M-10.9% | $3.7M+9.1% | $3.4M+11.4% | $3.0M+4.8% | $2.9M-7.8% | $3.1M+11.3% | $2.8M+12.4% | $2.5M |
| Gross Profit | $5.6M+0.8% | $5.6M+8.3% | $5.1M+7.8% | $4.8M-4.5% | $5.0M+10.2% | $4.5M+12.8% | $4.0M+22.6% | $3.3M |
| R&D Expenses | $3.5M-9.8% | $3.8M+13.3% | $3.4M+1.4% | $3.3M+6.8% | $3.1M+18.9% | $2.6M-1.0% | $2.7M+9.2% | $2.4M |
| SG&A Expenses | $3.6M+5.8% | $3.4M-17.0% | $4.1M+24.7% | $3.3M+18.7% | $2.8M-2.4% | $2.8M+3.9% | $2.7M-6.2% | $2.9M |
| Operating Income | -$5.3M+7.1% | -$5.7M+7.8% | -$6.2M-9.1% | -$5.6M-19.6% | -$4.7M-12.0% | -$4.2M+10.4% | -$4.7M+3.9% | -$4.9M |
| Interest Expense | -$543K-578.8% | -$80K-153.0% | $151K-33.2% | $226K-30.7% | $326K+193.7% | $111K+22.0% | $91K-9.0% | $100K |
| Income Tax | $8K-68.0% | $25K+38.9% | $18K+156.3% | -$32K-313.3% | $15K0.0% | $15K | N/A | N/A |
| Net Income | -$5.9M-0.9% | -$5.8M+3.1% | -$6.0M-11.9% | -$5.4M-22.2% | -$4.4M-6.3% | -$4.1M+10.2% | -$4.6M+4.0% | -$4.8M |
| EPS (Diluted) | $-0.210.0% | $-0.21+4.5% | $-0.22-10.0% | $-0.20-25.0% | $-0.160.0% | $-0.16+11.1% | $-0.18+10.0% | $-0.20 |
CLPT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $60.4M-4.0% | $62.9M+109.1% | $30.1M-23.3% | $39.2M-25.5% | $52.6M-2.0% | $53.6M+25.7% | $42.7M-2.7% | $43.8M |
| Current Assets | $51.3M-4.9% | $54.0M+123.0% | $24.2M-27.4% | $33.4M-28.3% | $46.6M-2.1% | $47.6M+31.5% | $36.2M-3.1% | $37.3M |
| Cash & Equivalents | $38.2M-8.0% | $41.5M+235.4% | $12.4M-38.4% | $20.1M-38.8% | $32.8M-7.1% | $35.4M+52.8% | $23.1M-4.9% | $24.3M |
| Inventory | $6.6M+4.6% | $6.3M-4.4% | $6.6M-4.1% | $6.9M-14.5% | $8.0M+0.9% | $8.0M+0.6% | $7.9M-12.0% | $9.0M |
| Accounts Receivable | $4.0M-6.1% | $4.3M+16.7% | $3.7M-22.5% | $4.7M+35.6% | $3.5M+38.4% | $2.5M-21.8% | $3.2M+32.5% | $2.4M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $44.5M+3.1% | $43.1M+327.7% | $10.1M-26.9% | $13.8M-32.5% | $20.4M+7.3% | $19.1M-11.3% | $21.5M+8.8% | $19.7M |
| Current Liabilities | $8.1M+8.9% | $7.4M+7.7% | $6.9M-33.7% | $10.4M-38.0% | $16.7M+10.1% | $15.2M+104.0% | $7.4M+32.9% | $5.6M |
| Long-Term Debt | $29.2M+1.2% | $28.8M | N/A | N/A | $10.0M+0.2% | $10.0M+0.2% | $9.9M+0.1% | $9.9M |
| Total Equity | $15.9M-19.6% | $19.7M-1.2% | $20.0M-21.3% | $25.4M-21.0% | $32.1M-7.1% | $34.6M+63.3% | $21.2M-12.1% | $24.1M |
| Retained Earnings | -$209.1M-2.9% | -$203.2M-3.0% | -$197.4M-3.1% | -$191.4M-5.7% | -$181.0M-2.5% | -$176.6M-2.4% | -$172.5M-2.8% | -$167.8M |
CLPT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M-22.3% | -$2.6M+58.7% | -$6.2M-377.3% | -$1.3M+51.5% | -$2.7M+30.5% | -$3.8M-228.5% | -$1.2M+34.9% | -$1.8M |
| Capital Expenditures | $199K+118.7% | $91K-50.3% | $183K-30.4% | $263K | $0 | $0-100.0% | $21K-91.1% | $235K |
| Free Cash Flow | -$3.3M-25.6% | -$2.6M+58.4% | -$6.4M-308.4% | -$1.6M+41.7% | -$2.7M+30.5% | -$3.8M-222.7% | -$1.2M+41.4% | -$2.0M |
| Investing Cash Flow | -$199K-118.7% | -$91K+50.3% | -$183K+30.4% | -$263K | $0 | $0+100.0% | -$188K+20.0% | -$235K |
| Financing Cash Flow | $0-100.0% | $32.0M+2447.8% | -$1.4M-3781.1% | $37K-76.9% | $160K-99.0% | $16.1M+10256.8% | $155K+270.3% | -$91K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CLPT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.2%+2.9pp | 60.3%-0.2pp | 60.5%-0.8pp | 61.3%-2.2pp | 63.5%+4.2pp | 59.2%+0.3pp | 58.9%+2.1pp | 56.8% |
| Operating Margin | -59.5%+2.1pp | -61.6%+11.0pp | -72.6%+0.1pp | -72.7%-12.6pp | -60.1%-4.9pp | -55.2%+13.9pp | -69.1%+15.9pp | -85.0% |
| Net Margin | -66.5%-3.1pp | -63.3%+7.7pp | -71.0%-1.7pp | -69.3%-13.2pp | -56.1%-1.8pp | -54.3%+13.6pp | -67.8%+15.6pp | -83.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.8%-0.5pp | -9.3%+10.8pp | -20.0%-6.3pp | -13.7%-5.4pp | -8.4%-0.7pp | -7.7%+3.1pp | -10.8%+0.1pp | -11.0% |
| Current Ratio | 6.37-0.9 | 7.30+3.8 | 3.53+0.3 | 3.22+0.4 | 2.79-0.3 | 3.14-1.7 | 4.87-1.8 | 6.68 |
| Debt-to-Equity | 1.84+0.4 | 1.46+1.0 | 0.50-0.0 | 0.54+0.2 | 0.31+0.0 | 0.29-0.2 | 0.47+0.1 | 0.41 |
| FCF Margin | -37.5%-8.8pp | -28.7%+46.2pp | -74.9%-54.9pp | -20.0%+13.9pp | -34.0%+16.3pp | -50.3%-32.8pp | -17.5%+17.8pp | -35.3% |
Similar Companies
Frequently Asked Questions
What is Clearpoint Neuro Inc's annual revenue?
Clearpoint Neuro Inc (CLPT) reported $31.4M in total revenue for fiscal year 2024. This represents a 31.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Clearpoint Neuro Inc's revenue growing?
Clearpoint Neuro Inc (CLPT) revenue grew by 31% year-over-year, from $24.0M to $31.4M in fiscal year 2024.
Is Clearpoint Neuro Inc profitable?
No, Clearpoint Neuro Inc (CLPT) reported a net income of -$18.9M in fiscal year 2024, with a net profit margin of -60.3%.
What is Clearpoint Neuro Inc's earnings per share (EPS)?
Clearpoint Neuro Inc (CLPT) reported diluted earnings per share of $-0.70 for fiscal year 2024. This represents a 22.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Clearpoint Neuro Inc's EBITDA?
Clearpoint Neuro Inc (CLPT) had EBITDA of -$18.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Clearpoint Neuro Inc's gross margin?
Clearpoint Neuro Inc (CLPT) had a gross margin of 60.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Clearpoint Neuro Inc's operating margin?
Clearpoint Neuro Inc (CLPT) had an operating margin of -62.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Clearpoint Neuro Inc's net profit margin?
Clearpoint Neuro Inc (CLPT) had a net profit margin of -60.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Clearpoint Neuro Inc's free cash flow?
Clearpoint Neuro Inc (CLPT) generated -$9.3M in free cash flow during fiscal year 2024. This represents a 35.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Clearpoint Neuro Inc's operating cash flow?
Clearpoint Neuro Inc (CLPT) generated -$9.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Clearpoint Neuro Inc's total assets?
Clearpoint Neuro Inc (CLPT) had $39.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Clearpoint Neuro Inc's capital expenditures?
Clearpoint Neuro Inc (CLPT) invested $275K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Clearpoint Neuro Inc spend on research and development?
Clearpoint Neuro Inc (CLPT) invested $12.4M in research and development during fiscal year 2024.
How many shares does Clearpoint Neuro Inc have outstanding?
Clearpoint Neuro Inc (CLPT) had 28M shares outstanding as of fiscal year 2024.
What is Clearpoint Neuro Inc's current ratio?
Clearpoint Neuro Inc (CLPT) had a current ratio of 3.22 as of fiscal year 2024, which is generally considered healthy.
What is Clearpoint Neuro Inc's debt-to-equity ratio?
Clearpoint Neuro Inc (CLPT) had a debt-to-equity ratio of 0.54 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Clearpoint Neuro Inc's return on assets (ROA)?
Clearpoint Neuro Inc (CLPT) had a return on assets of -48.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Clearpoint Neuro Inc's cash runway?
Based on fiscal year 2024 data, Clearpoint Neuro Inc (CLPT) had $20.1M in cash against an annual operating cash burn of $9.0M. This gives an estimated cash runway of approximately 27 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Clearpoint Neuro Inc's Piotroski F-Score?
Clearpoint Neuro Inc (CLPT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clearpoint Neuro Inc's earnings high quality?
Clearpoint Neuro Inc (CLPT) has an earnings quality ratio of 0.48x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Clearpoint Neuro Inc cover its interest payments?
Clearpoint Neuro Inc (CLPT) has an interest coverage ratio of -22.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Clearpoint Neuro Inc?
Clearpoint Neuro Inc (CLPT) scores 58 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.